Nimodipine clinical trials
Nimodipine is named as an intervention in 2 current clinical trials in our Switzerland and Canada registers. 1 is recruiting patients now. The most common phase is Not applicable. The sponsor with the most trials is Hans-Peter Landolt (1). The most-studied condition is Mediation of 5G Effects on Sleep.
Where Nimodipine is approved
All regulators →Of the three regulators tracked here, the first to approve Nimodipine was the US, on 28 Dec 1988.
- 1 EU orphan designation, most recently for treatment of aneurysmal subarachnoid haemorrhage (9 Oct 2015, positive)
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
Nimodipine patents and exclusivity
Expiry tracker →Protections still running for marketed products containing Nimodipine, as listed by the regulators. Expired patents and exclusivities, and discontinued products, are not shown.
- 6 listed patents; the last listed expires 16 Apr 2038 (US 11413277).
Reproduced from the FDA Orange Book and Purple Book (checked 8 Nov 2026) and the European Commission's Union Register of medicinal products (CC BY 4.0; the EU expiry date is calculated exactly as the Commission's register displays it). Listed patents and dates are as submitted to or published by the regulator and may not reflect litigation, invalidation, settlements, lapsed fees or later extensions. This is not legal advice or a freedom-to-operate opinion, and it does not say when a generic or biosimilar will launch.
What health systems spend on Nimodipine
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Nimodipine works
All drug targets →- Mineralocorticoid receptor antagonist AntagonistTarget: NR3C2 nuclear receptor subfamily 3 group C member 2✓ In ChEMBL and the Guide to Pharmacology
- Voltage-gated L-type calcium channel blocker BlockerTarget: Voltage-gated L-type calcium channel✓ In ChEMBL and the Guide to Pharmacology
- Subarachnoid hemorrhagePhase 3
- Mental deteriorationPhase 2
- Acoustic neuromaPhase 2
- Cocaine dependencePhase 2
- AIDS dementia complexPhase 1
- Cocaine abusePhase 1
- Frontotemporal dementiaPhase 1
- SchizophreniaEarly phase 1
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL1428, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 2523, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Nimodipine
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 2 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Nimodipine
- ATC code
- C08CA06
- ChEMBL
- CHEMBL1428
- DrugBank
- DB00393
- PubChem CID
- 4497
- CAS number
- 66085-59-4
- FDA UNII
- 57WA9QZ5WH
- Wikidata
- Q421429
- Wikipedia
- Nimodipine
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Nimodipine
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Causal Role for Voltage-gated Cav1.2 Calcium Channels in Mediating 5G FR1 Effects on Sleep-associated Brain Health in Humans
NCT06998368 · ClinicalTrials.gov ↗ · Mediation of 5G Effects on Sleep
|
Not applicable | Recruiting | Hans-Peter Landolt | Switzerland |
|
Pharmacological Mechanisms of Low-intensity Focused Ultrasound for Motor Cortex Neuroplasticity
NCT04923659 · ClinicalTrials.gov ↗ · Low Intensity Focussed Ultrasound
|
Early Phase 1 | Active, closed | University Health Network, Toronto | Canada |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Nimodipine across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
2 single-substance products containing Nimodipine on the HPRA medicines list.
- Nimotop 0.02% w/v Concentrate for Solution for InfusionLaboratoire X.O · PA25299/001/002 · Marketed
- Nimotop 30 mg film-coated tabletsLaboratoire X.O · PA25299/001/001 · Marketed
Supply shortages
No entry for Nimodipine in the EMA, FDA or German BfArM shortage lists we track.
Conditions studied with Nimodipine
2 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Hans-Peter Landolt | 1 |
| University Health Network, Toronto | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Switzerland | 1 | 1 |
| Clinical trials in Canada | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Nimodipine trials
How many clinical trials are testing Nimodipine?
2 current trials in our Switzerland and Canada registers name Nimodipine as a drug or biological intervention, as of the registry sync on 12 November 2026. Completed and withdrawn studies are not counted.
Are Nimodipine trials recruiting patients?
Yes. 1 of the 2 trials is recruiting: 1 with sites in Switzerland. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Nimodipine clinical trials?
Hans-Peter Landolt (1) and University Health Network, Toronto (1). The number in brackets is how many trials each organisation leads.
Is Nimodipine licensed in Ireland?
Yes. The HPRA medicines list includes 2 single-substance products containing Nimodipine, for example Nimotop 0.02% w/v Concentrate for Solution for Infusion (Laboratoire X.O). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Nimodipine shortage?
Not in the lists we track: Nimodipine has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Nimodipine works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Nimodipine works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Nimodipine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 12 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.